The University of Chicago Header Logo

Connection

Marina Chiara Garassino to Immunotherapy

Back to Details
This is a "connection" page, showing publications Marina Chiara Garassino has written about Immunotherapy.
Marina Chiara Garassino
Connection Strength
4.248
Immunotherapy
  1. Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC. J Thorac Oncol. 2024 Jun; 19(6):877-882.
    View in: PubMed
    Score: 0.610
  2. Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. Immunotherapy. 2021 05; 13(7):621-631.
    View in: PubMed
    Score: 0.489
  3. Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet. Tumori. 2016 Jun 02; 2016(3):223-5.
    View in: PubMed
    Score: 0.345
  4. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2010 Nov; 70(2):119-28.
    View in: PubMed
    Score: 0.227
  5. Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review. Lung Cancer. 2025 Jan; 199:108051.
    View in: PubMed
    Score: 0.158
  6. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024 May 30; 23(1):115.
    View in: PubMed
    Score: 0.152
  7. Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 11; 23(7):e489-e499.
    View in: PubMed
    Score: 0.134
  8. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. Eur J Cancer. 2021 06; 150:224-231.
    View in: PubMed
    Score: 0.123
  9. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 03 01; 39(7):723-733.
    View in: PubMed
    Score: 0.121
  10. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know. J Exp Clin Cancer Res. 2020 Nov 09; 39(1):236.
    View in: PubMed
    Score: 0.119
  11. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. Clin Lung Cancer. 2020 09; 21(5):e337-e348.
    View in: PubMed
    Score: 0.114
  12. Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. Lung Cancer. 2020 04; 142:70-79.
    View in: PubMed
    Score: 0.113
  13. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer. 2019 11; 137:38-42.
    View in: PubMed
    Score: 0.110
  14. Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. Future Oncol. 2019 Aug; 15(23):2743-2757.
    View in: PubMed
    Score: 0.109
  15. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Lung Cancer. 2019 06; 132:72-78.
    View in: PubMed
    Score: 0.107
  16. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev. 2019 May; 75:39-51.
    View in: PubMed
    Score: 0.106
  17. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 2019 03; 129:35-40.
    View in: PubMed
    Score: 0.105
  18. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. Target Oncol. 2018 12; 13(6):795-800.
    View in: PubMed
    Score: 0.104
  19. Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity. Cancer Res. 2018 10 15; 78(20):5729-5730.
    View in: PubMed
    Score: 0.103
  20. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018 06; 120:62-69.
    View in: PubMed
    Score: 0.099
  21. Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. Eur Respir J. 2018 02; 51(2).
    View in: PubMed
    Score: 0.099
  22. Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. Curr Oncol Rep. 2016 09; 18(9):59.
    View in: PubMed
    Score: 0.089
  23. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? Tumori. 2016 Jan-Feb; 102(1):18-30.
    View in: PubMed
    Score: 0.084
  24. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024 Sep 26; 10(1):71.
    View in: PubMed
    Score: 0.039
  25. DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
    View in: PubMed
    Score: 0.039
  26. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy. J Exp Clin Cancer Res. 2024 Jan 02; 43(1):6.
    View in: PubMed
    Score: 0.037
  27. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT). Lung Cancer. 2024 01; 187:107441.
    View in: PubMed
    Score: 0.037
  28. Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations. Clin Lung Cancer. 2023 11; 24(7):631-640.e2.
    View in: PubMed
    Score: 0.036
  29. The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. Clin Lung Cancer. 2023 06; 24(4):381-387.
    View in: PubMed
    Score: 0.035
  30. Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. Future Oncol. 2022 Jul; 18(23):2593-2604.
    View in: PubMed
    Score: 0.033
  31. Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. Cancer Immunol Immunother. 2021 Sep; 70(9):2429-2438.
    View in: PubMed
    Score: 0.031
  32. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. Lung Cancer. 2021 02; 152:165-173.
    View in: PubMed
    Score: 0.030
  33. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. Lung Cancer. 2020 12; 150:123-131.
    View in: PubMed
    Score: 0.030
  34. Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. Clin Cancer Res. 2021 01 15; 27(2):492-503.
    View in: PubMed
    Score: 0.029
  35. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. Clin Cancer Res. 2019 04 01; 25(7):2166-2173.
    View in: PubMed
    Score: 0.026
  36. The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. Tumori. 2018 Mar-Apr; 104(2):88-95.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.